No Data
Sony Group Corp has revised its forecast upwards for March 25, with operating profit of 1 trillion 335 billion yen, up from 1 trillion 310 billion yen.
Sony Group Corp (6758) announced a revision of its Financial Estimates for the fiscal year ending March 2025. Revenue has been revised upwards from 12 trillion 710 billion yen to 13 trillion 200 billion yen, and operating profit from 1 trillion 310 billion yen to 1 trillion 335 billion yen. Entertainment-related segments such as Gaming and music are performing steadily. Additionally, it was announced that a share buyback program with a cap of 50 billion yen has been established, allowing the purchase of up to 30 million shares (0.5% of the total issued shares excluding treasury shares) in the market. 【Positive evaluation】<675
Universal Entertainment: Notice regarding the recording of non-operating income (foreign exchange gains), corporate tax adjustments, etc., and differences between full-year consolidated earnings forecasts and actual values
Universal Entertainment: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (consolidated)
Universal Entertainment's Subsidiary to Transfer Asiabest Group Shares to Premiumlands
Japan Machinery Orders Decline 2.9% in September
Mitsubishi UFJ, 2Q operating profit increased by 37.3% to 1.7569 trillion yen, announced a share buyback.
Mitsubishi UFJ <8306> announced its second-quarter results for the fiscal year ending March 2025, with operating revenue increasing by 21.1% year-on-year to 6 trillion 860.2 billion 77 million yen, and ordinary profit rising by 37.3% to 1 trillion 756.9 billion 26 million yen. Additionally, the net profit forecast for the fiscal year ending March 2025 was revised upwards from 1 trillion 500 billion yen to 1 trillion 750 billion yen. This was due to strong performance in the customer division, as well as improvements in profit margins from rising yen interest rates and the sale of shareholdings. The annual dividends plan is set at 60 yen per share, in line with previous indications.
